SAN DIEGO — Combination cagrilintide and semaglutide therapy is associated with a 15.6% weight loss and 2.2% reduction in HbA1c among adults with obesity and type 2 diabetes, according to a speaker.In findings from a phase 2a trial that were presented at the American Diabetes Association Scientific Sessions and simultaneously published in The Lancet, 71% of adults receiving coadministered